253 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review Table 3. Continued Reference Level of Testing Name Genes, Molecules or Panel Investigated Type of Analysis Performed Gene or Molecule Name and Mutation or Expression Status (n) No. of Patients with PM (N) and Outcomes (n) No. of Patients without PM (N) and Outcomes (n) MMR Status (MSI/MSS) Findings as Reported by Authors in Studies Sasaki et al. 33 DNA BRAF, KRAS, PIK3CA PCR N = 117 N = 409 N/A The PM group had a significantly higher incidence of the BRAF V600E mutation than the non-PM group (27.7% vs. 7.3%, p < 0.01 d). In contrast, no differences were observed between the two groups in KRAS and PIK3CA mutations (p 0.42 d and 0.76,d respectively). KRAS wild-type 54 163 KRAS mutation 46 115 BRAF wild-type 34 115 BRAF mutation 13 9 PIK3CA wild-type 53 181 PIK3CA mutation 5 20 Sayagués et al. 34 DNA KRAS/NRAS, BRAF and TP53 NGS N = 7 N = 80 Total: 6/48 BRAF-mutated CRC tumors were significantly associated with PM (p = 0.006d). KRAS mutant (24) 1 23 0/16 NRAS mutant (1) 0 1 0/0 BRAF mutant (6) 3 3 3/2 TP53 mutant (29) 2 27 1/21 Schirripa et al. 47 - KRAS Sanger sequencing, Sequenom MassArray N = 108 N = 391 N/A Compared to other KRAS- mutated cases, KRAS G12C mutations had a lower frequency in PM patients (13.5% vs. 25%, p = 0.008 d). KRAS mutant (694) 90 276 KRAS G12C mutant (145) 18 115 11
RkJQdWJsaXNoZXIy MTk4NDMw